These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

523 related items for PubMed ID: 23312990

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Chemoembolization for hepatocellular carcinoma: 1-month response determined with apparent diffusion coefficient is an independent predictor of outcome.
    Vandecaveye V, Michielsen K, De Keyzer F, Laleman W, Komuta M, Op de beeck K, Roskams T, Nevens F, Verslype C, Maleux G.
    Radiology; 2014 Mar; 270(3):747-57. PubMed ID: 24475816
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma.
    Niessen C, Unterpaintner E, Goessmann H, Schlitt HJ, Mueller-Schilling M, Wohlgemuth WA, Stroszczynski C, Wiggermann P.
    J Vasc Interv Radiol; 2014 Feb; 25(2):240-7. PubMed ID: 24291001
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma.
    Prajapati HJ, Dhanasekaran R, El-Rayes BF, Kauh JS, Maithel SK, Chen Z, Kim HS.
    J Vasc Interv Radiol; 2013 Mar; 24(3):307-15. PubMed ID: 23375519
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Kloeckner R, Otto G, Biesterfeld S, Oberholzer K, Dueber C, Pitton MB.
    Cardiovasc Intervent Radiol; 2010 Jun; 33(3):532-40. PubMed ID: 19847482
    [Abstract] [Full Text] [Related]

  • 11. Drug-eluting bead loaded with doxorubicin versus conventional Lipiodol-based transarterial chemoembolization in the treatment of hepatocellular carcinoma: a case-control study of Asian patients.
    Song MJ, Park CH, Kim JD, Kim HY, Bae SH, Choi JY, Yoon SK, Chun HJ, Choi BG, Lee HG.
    Eur J Gastroenterol Hepatol; 2011 Jun; 23(6):521-7. PubMed ID: 21537127
    [Abstract] [Full Text] [Related]

  • 12. C-arm Lipiodol CT in transcatheter arterial chemoembolization for small hepatocellular carcinoma.
    Li JJ, Zheng JS, Cui SC, Cui XW, Hu CX, Fang D, Ye LC.
    World J Gastroenterol; 2015 Mar 14; 21(10):3035-40. PubMed ID: 25780303
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Baseline and Early MR Apparent Diffusion Coefficient Quantification as a Predictor of Response of Unresectable Hepatocellular Carcinoma to Doxorubicin Drug-Eluting Bead Chemoembolization.
    Kokabi N, Ludwig JM, Camacho JC, Xing M, Mittal PK, Kim HS.
    J Vasc Interv Radiol; 2015 Dec 14; 26(12):1777-86. PubMed ID: 26603497
    [Abstract] [Full Text] [Related]

  • 20. EASL- and mRECIST-evaluated responses to combination therapy of sorafenib with transarterial chemoembolization predict survival in patients with hepatocellular carcinoma.
    Liu L, Wang W, Chen H, Zhao Y, Bai W, Yin Z, He C, Jia J, Yang M, Xia J, Fan D, Han G.
    Clin Cancer Res; 2014 Mar 15; 20(6):1623-31. PubMed ID: 24493832
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.